Global Hereditary Testing Market Size, Trends & Analysis - Forecasts to 2026

The results analyzed by GME showed that the Global Hereditary Testing Market will grow with a CAGR value of 7.1 percent, to hit xx billion USD by 2026. During the forecast timeframe, growth is expected to be driven by growing expenditure on R&D activities and the rising incidence of chronic diseases worldwide. The development may be attributed to the advancement of genetic testing services and the growing demand for personalized medicine.

Browse 153 Market Data Tables and 113 Figures spread through 183 Pages and in-depth TOC on "Hereditary Testing Market – Forecast to 2026"

https://www.globalmarketestimates.com/market-report/global-hereditary-testing-market-2591

By Type of Disease (Hereditary Cancer Testing, Hereditary Non-Cancer Testing), By Region (North America, Asia Pacific, CSA, Europe, and the Middle East and Africa); End-User Landscape, Company Market Share Analysis & Competitor Analysis

Key Market Insights

The increasing adoption of innovative therapies to drive the growth of the market
The rising demand for DNA test procedures will help the market grow tremendously from 2021 to 2026
The increasing awareness of early screening of genetic conditionsis projected to fuel the market demand in the coming years

Myriad Genetics, Inc., Illumina, Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Blueprint Genetics, Agilent Technologies, Inc., Twist Bioscience, Fulgent Genetics, Inc., CENTOGENE N.V., BG Genomic, Invitae Corporation, Natera Inc., F. Hoffmann-La Roche Ltd., CooperSurgical, Inc., Thermo Fisher Scientific, Inc., Sophia Genetics, and Medgenomeare the main competitors of the market.

Browse the Report @https://www.globalmarketestimates.com/market-report/global-hereditary-testing-market-2591

Type of Disease Outlook (Revenue, USD Billion, 2021-2026)

Hereditary Cancer Testing
- Lung Cancer
- Colorectal Cancer
- Breast Cancer
- Cervical Cancer
- Stomach/Gastric Cancer
- Melanoma
- Ovarian Cancer
- Prostate Cancer
- Sarcoma
- Pancreatic Cancer
- Uterine Cancer
- Other Cancers
Hereditary Non-Cancer Testing
- Hereditary Non-Cancer Genetic Testing
- Newborn Genetic Screening
- Non-invasive prenatal testing (NIPT) & carrier screening